About Elypta
Elypta is a company based in Stockholm (Sweden) founded in 2017. Elypta has raised $27.85 million across 5 funding rounds from investors including European Commission, European Union and Chalmers Ventures. Elypta offers products and services including MIRAM® Kit. Elypta operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Elypta Ab
-
Annual Revenue
$46.88 K (USD)46as on Dec 31, 2018
-
Net Profit
-$648.44 K (USD)-320as on Dec 31, 2018
-
EBITDA
Not available
-
Total Equity Funding
$27.85 M (USD)
in 5 rounds
-
Latest Funding Round
$21 M (USD), Series A
Jun 20, 2022
-
Investors
European Commission
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Elypta
Elypta offers a comprehensive portfolio of products and services, including MIRAM® Kit.
Urine test for detecting cancer through GAGome biomarkers and machine learning analysis
People of Elypta
Unlock access to complete
Funding Insights of Elypta
Elypta has successfully raised a total of $27.85M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $21 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Elypta
Elypta has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Commission, European Union and Chalmers Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Navigare Ventures is focused on early-stage science-driven investments.
|
Locked | Locked | Locked | |
|
Investments in deep-tech, life sciences, and transformative tech are managed.
|
Locked | Locked | Locked | |
|
Impact investments are made in startups addressing global challenges.
|
Locked | Locked | Locked |
Investor details for Elypta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Elypta
Investment portfolio details for Elypta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Elypta
Detailed financials for Elypta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Elypta Comparisons
Peer comparison for Elypta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Elypta
Elypta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Elypta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Elypta
Complete news archive for Elypta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elypta
Elypta was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Elypta is headquartered in Stockholm, Sweden.
Elypta is a funded company, having raised a total of $27.85M across 5 funding rounds to date.
Annual revenue of Elypta is $46.88K as on Dec 31, 2018.
Elypta was founded in 2017 in Stockholm, Sweden, and operates in the biotechnology sector. A liquid biopsy platform is utilized for detecting and monitoring cancer, primarily renal cell carcinoma. Biomarkers are measured, and machine learning algorithms are applied to generate scores against cancer-specific signatures. The platform supports early detection, differential diagnosis, treatment response monitoring, and prediction, often replacing or supplementing medical imaging.
Elypta's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Elypta offers MIRAM® Kit.
Elypta has 11 investors. Key investors include European Commission, European Union, Chalmers Ventures, Sciety, and Navigare Ventures.